On May 26, 2026, Arbutus Biopharma Corp. shareholders approved a new 2026 Omnibus Share and Incentive Plan allowing the issuance of 16.3 million common shares, alongside electing board members and appointing Ernst & Young LLP as auditors for 2026. The event is significant with a positive sentiment for investors.